Original Paper

Topical Mitomycin C for the Treatment of Conjunctival Tumor
Altan Atakan Ozcan, Selcuk Sizmaz, Meltem Yagmur

Department of Ophthalmology, Faculty of Medicine, Çukurova University, Adana, Turkey

Address of Corresponding Author

Ophthalmologica 2007;221:14-17 (DOI: 10.1159/000096516)

  Key Words

• Mitomycin C
• Conjunctival tumor
• Tumor control

  Abstract

Background: To evaluate the efficacy of topical mitomycin C (MMC) for the treatment of conjunctival tumor in a prospective design. Methods: Nine patients (nine eyes) with conjunctival tumor were studied. The patients received topical MMC 0.04% four times daily by one to six courses. Each course consisted of medication for consecutive 7 days followed by 1 week without medication. Follow-up was conducted on patients for control of disease, and side effects. Results: In 7 patients, the tumor completely disappeared during the mean follow-up period of 24.57 ± 5.94 months (range 18-35 months) with no recurrence. In 1 patient, there was no regression of the tumor, and in 1 patient cessation of the treatment was needed because of an adverse effect of the drug. Conclusion: Topical MMC is effective for the treatment of conjunctival tumor. Longer follow-up and large series are needed to assess the duration of tumor control.

Copyright © 2007 S. Karger AG, Basel

  Author Contacts

Altan Atakan Ozcan, MD
Department of Ophthalmology
Çukurova University Medical Faculty
TR-01330 Balcali, Adana (Turkey)
Tel./Fax +90 322 338 6442, E-Mail altanoz@cu.edu.tr

  Article Information

Received: February 16, 2006
Accepted after revision: April 21, 2006
Number of Print Pages : 4
Number of Figures : 4, Number of Tables : 1, Number of References : 11